Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Cancer Clinical Research Trust
University College Dublin
- License Information
-
More Information
Article History
Accepted: 29 July 2025
First Online: 15 August 2025
Declarations
:
: Cancer Clinical Research Trust.
: MJD and MT, no conflicts of interest. JC: Research funding (to institution): Eisai, Puma Biotechnology, Roche, Boehringer Ingelheim; Employment: OncoMark, Ltd.; Honoraria: Eisai, Puma Biotechnology; MSD Oncology, Pfizer, G1 Therapeutics; Novartis; Speaker’s Bureau: Boehringer Ingelheim, Genomic Health, Roche, Pfizer; Shares: OncoMark Ltd; Travel and accommodation expenses: Pfizer, MSD, Abbvie, Astrazeneca, Novartis.
: Not applicable.
: Not applicable.
: Not applicable.
: M.J.D. conceptualized and drafted the original version of the manuscript. M.T. and J.C. revised the manuscript with J.C. making a specific contribution to the clinical aspects discussed in the manuscript. All authors have read and agreed to the published version of the manuscript.
